[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Figure 1.
Toll-like receptor (TLR) 2, TLR3, and TLR4 signaling pathways. Deficiency both in myeloid differentiation factor 88 (MyD88) and Toll-interleukin 1 (IL-1) receptor domain-containing adaptor-inducing interferon β (TRIF) results in complete loss of nuclear factor κB (NF-κB) activation, a factor that has a central role in inflammatory cytokine production. dsRNA indicates double-stranded RNA; IRAK, IL-1 receptor–associated kinase; IRF-3, interferon regulatory factor 3; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; PGN, peptidoglycans; TIRAP, Toll-IL-1 receptor domain–containing adaptor protein; Tollip, Toll-interacting protein; and TRAF6, tumor necrosis factor receptor–associated factor 6.

Toll-like receptor (TLR) 2, TLR3, and TLR4 signaling pathways. Deficiency both in myeloid differentiation factor 88 (MyD88) and Toll-interleukin 1 (IL-1) receptor domain-containing adaptor-inducing interferon β (TRIF) results in complete loss of nuclear factor κB (NF-κB) activation, a factor that has a central role in inflammatory cytokine production. dsRNA indicates double-stranded RNA; IRAK, IL-1 receptor–associated kinase; IRF-3, interferon regulatory factor 3; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; PGN, peptidoglycans; TIRAP, Toll-IL-1 receptor domain–containing adaptor protein; Tollip, Toll-interacting protein; and TRAF6, tumor necrosis factor receptor–associated factor 6.

Figure 2.
Surgically relevant Toll-like receptor (TLR) pathways and their associations with various surgical diseases. AMI indicates acute myocardial infarction; CAD, coronary artery disease; IRAK, interleukin 1 receptor–associated kinase; MyD88, myeloid differentiation factor 88; and SIRS, systemic inflammatory response syndrome.

Surgically relevant Toll-like receptor (TLR) pathways and their associations with various surgical diseases. AMI indicates acute myocardial infarction; CAD, coronary artery disease; IRAK, interleukin 1 receptor–associated kinase; MyD88, myeloid differentiation factor 88; and SIRS, systemic inflammatory response syndrome.

1.
Lemaitre  BNicolas  EMichaut  L  et al.  The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86973- 983
PubMedArticle
2.
Iwasaki  AMedzhitov  R Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5987- 995
PubMedArticle
3.
Medzhitov  R Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1135- 145
PubMedArticle
4.
Visintin  ALatz  EMonks  BG  et al.  Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem 2003;27848 313- 48 320
PubMedArticle
5.
Nagai  YAkashi  SNagafuku  M  et al.  Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002;3667- 672
PubMed
6.
Jiang  QAkashi  SMiyake  K  et al.  Cutting edge: lipopolysaccharide induces physical proximity between CD14 and Toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-B. J Immunol 2000;1653541- 3544
PubMedArticle
7.
Visintin  AMazzoni  ASpitzer  JA  et al.  Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci U S A 2001;9812156- 12161. Epub 2001 Oct 2
PubMedArticle
8.
Kawai  TAdachi  OOgawa  T  et al.  Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999;11115- 122
PubMedArticle
9.
Takeuchi  OHoshino  KAkira  S Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000;1655392- 5396
PubMedArticle
10.
Takeuchi  OKaufmann  AGrote  K  et al.  Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway. J Immunol 2000;164554- 557
PubMedArticle
11.
Suzuki  NSuzuki  SDuncan  GS  et al.  Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4. Nature 2002;416750- 756
PubMedArticle
12.
Horng  TBarton  GMMedzhitov  R TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2001;2835- 841
PubMedArticle
13.
Fitzgerald  KAPalsson-McDermott  EMBowie  AG  et al.  Mal (MyD88-adaptor-like) is required for Toll-like receptor-4 signal transduction. Nature 2001;41378- 83
PubMedArticle
14.
Yamamoto  MSato  SHemmi  H  et al.  Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 2003;301640- 643
PubMedArticle
15.
Johnson  GBBrunn  GJPlatt  JL Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol 2004;17220- 24
PubMedArticle
16.
Armstrong  LMedford  ARHunter  KJUppington  KMMillar  AB Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol 2004;136312- 319
PubMedArticle
17.
Harter  LMica  LStocker  RTrentz  OKeel  M Increased expression of toll-like receptor-2 and -4 on leukocytes from patients with sepsis. Shock 2004;22403- 409
PubMedArticle
18.
Bihl  FSalez  LBeaubier  M  et al.  Overexpression of Toll-Like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J Immunol 2003;1706141- 6150
PubMedArticle
19.
Wang  MJeng  KCPing  LI Exogenous cytokine modulation or neutralization of interleukin-10 enhance survival in lipopolysaccharide-hyporesponsive C3H/HeJ mice with Klebsiella infection. Immunology 1999;9890- 97
PubMedArticle
20.
Williams  DLHa  TLi  C  et al.  Modulation of tissue Toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit Care Med 2003;311808- 1818
PubMedArticle
21.
Weighardt  HKaiser-Moore  SVabulas  RM  et al.  Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol 2002;1692823- 2827
PubMedArticle
22.
Feterowski  CEmmanuilidis  KMiethke  T  et al.  Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 2003;109426- 431
PubMedArticle
23.
Holmes  CLRussell  JAWalley  KR Genetic polymorphism in sepsis and septic shock. Chest 2003;1241103- 1115
PubMedArticle
24.
Arbour  NCLorenz  ESchutte  BC  et al.  TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25187- 191
PubMedArticle
25.
Agnese  DMCalvano  JEHahm  SJ  et al.  Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;1861522- 1525
PubMedArticle
26.
Lorenz  EMira  JPFrees  KL  et al.  Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002;1621028- 1032
PubMedArticle
27.
Erridge  CStewart  JPoxton  IR Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003;1971787- 1791
PubMedArticle
28.
Imahara  SDJelacic  SJunker  CEO'Keefe  GE The TLR4 +896 polymorphism is not associated with lipopolysaccharide hypo-responsiveness in leukocytes. Genes Immun 2005;637- 43
PubMedArticle
29.
Hamann  LKumpf  OMuller  M  et al.  A coding mutation within the first exon of the human MD-2 gene results in decreased lipopolysaccharide-induced signaling. Genes Immun 2004;5283- 288
PubMedArticle
30.
Lorenz  EMira  JPCornish  KL  et al.  A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000;686398- 6401
PubMedArticle
31.
Meng  GRutz  MSchiemann  M  et al.  Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 2004;1131473- 1481
PubMedArticle
32.
Picard  CPuel  ABonnet  M  et al.  Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003;2992076- 2079
PubMedArticle
33.
Wang  JHDoyle  MManning  BJ  et al.  Induction of bacterial lipoprotein tolerance is associated with suppression of Toll-like receptor 2 expression. J Biol Chem 2002;27736 068- 36 075
PubMedArticle
34.
Dobrovolskaia  MAMedvedev  AEThomas  KE  et al.  Induction of in vitro reprogramming by Toll-Like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR “homotolerance” versus “heterotolerance” on NF-kB signaling pathway components. J Immunol 2003;170508- 519
PubMedArticle
35.
Sato  STakeuchi  OFujita  T  et al.  A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. Int Immunol 2002;14783- 791
PubMedArticle
36.
Medvedev  AEHenneke  PSchromm  A  et al.  Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J Immunol 2001;1672257- 2267
PubMedArticle
37.
Mizel  SBSnipes  JA Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from Toll-like receptor 5. J Biol Chem 2002;27722 414- 22 420
PubMedArticle
38.
Medvedev  AELentschat  AWahl  LM  et al.  Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 2002;1695209- 5216
PubMedArticle
39.
Kobayashi  KHernandez  LDGalaìn  JE  et al.  IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002;110191- 202
PubMedArticle
40.
Wang  JHDoyle  MManning  BJ  et al.  Cutting edge: bacterial lipoprotein induces endotoxin-independent tolerance to septic shock. J Immunol 2003;17014- 18
PubMedArticle
41.
O'Brien  GCWang  JHRedmond  HP Bacterial lipoprotein induces resistance to gram-negative sepsis in TLR4-deficient mice via enhanced bacterial clearance. J Immunol 2005;1741020- 1026
PubMedArticle
42.
Iwami  KIMatsuguchi  TMasuda  A  et al.  Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2000;1656682- 6686
PubMedArticle
43.
Pugin  JStern-Voeffray  SDaubeuf  BMatthay  MAElson  GDunn-Siegrist  I Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood 2004;1044071- 4079
PubMedArticle
44.
Kennedy  MNMullen  GELeifer  CA  et al.  A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem 2004;27934 698- 34 704
PubMedArticle
45.
Romics  L  JrDolganiuc  AKodys  K  et al.  Selective priming to Toll-like receptor 4 (TLR4), not TLR2, ligands by P. acnes involves up-regulation of MD-2. Hepatology 2004;40555- 564
PubMedArticle
46.
Murphy  TJPaterson  HMKriyonovich  S  et al.  Linking the “two-hit” response following injury to enhanced TLR4 reactivity. J Leukoc Biol 2005;7716- 23
PubMed
47.
Park  JSSvetkauskaite  DHe  Q  et al.  Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;2797370- 7377
PubMedArticle
48.
Abreu  MTVora  PFaure  E  et al.  Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;1671609- 1616
PubMedArticle
49.
Gewirtz  ATNavas  TALyons  S  et al.  Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001;1671882- 1885
PubMedArticle
50.
Rakoff-Nahoum  SPaglino  JEslami-Varzaneh  FEdberg  SMedzhitov  R Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118229- 241
PubMedArticle
51.
Cario  EPodolsky  DK Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;687010- 7017
PubMedArticle
52.
Ortega-Cava  CFIshihara  SRumi  MAK  et al.  Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol 2003;1703977- 3985
PubMedArticle
53.
Hugot  JPChamaillard  MZouali  H  et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411599- 603
PubMedArticle
54.
Ogura  YBonen  DKInohara  N  et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411603- 606
PubMedArticle
55.
Rachmilewitz  DKatakura  KKarmeli  F  et al.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126520- 528
PubMedArticle
56.
Torok  HPGlas  JTonenchi  LMussack  TFolwaczny  C Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004;11285- 91
PubMedArticle
57.
Franchimont  DVermeire  SEl Housni  H  et al.  Deficient host-bacteria interactions in inflammatory bowel disease? the toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004;53987- 992
PubMedArticle
58.
Lodes  MJCong  YElson  CO  et al.  Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;1131296- 1306
PubMedArticle
59.
Bambou  JCGiraud  AMenard  S  et al.  In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain. J Biol Chem 2004;27942 984- 42 992
PubMedArticle
60.
Maaser  CHeidemann  Jvon Eiff  C  et al.  Human intestinal microvascular endothelial cells express Toll-like receptor 5: a binding partner for bacterial flagellin. J Immunol 2004;1725056- 5062
PubMedArticle
61.
Su  BCeponis  PJMLebel  S  et al.  Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect Immun 2003;713496- 3502
PubMedArticle
62.
Bäckhed  FRokbi  BTorstensson  E  et al.  Gastric mucosal recognition of Helicobacter pylori is independent of Toll-like receptor 4. J Infect Dis 2003;187829- 836
PubMedArticle
63.
Gewirtz  ATYu  YKrishna  USIsrael  DALyons  SLPeek  RM  Jr Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004;1891914- 1920
PubMedArticle
64.
Wald  NJLaw  MRMorris  JK  et al.  Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 2000;321204- 207
PubMedArticle
65.
Petersen  EBoman  JPersson  K  et al.  Chlamydia pneumoniae in human abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1998;15138- 142
PubMedArticle
66.
Juvonen  JJuvonen  TLaurila  K  et al.  Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997;25499- 505
PubMedArticle
67.
Xu  QSchett  GPerschinka  H  et al.  Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 2000;10214- 20
PubMedArticle
68.
Pockley  AGWu  RLemne  CKiessling  Rde Faire  UFrostegard  J Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension 2000;36303- 307
PubMedArticle
69.
Sasu  SLaVerda  DQureshi  N  et al.  Chlamydia pneumoniae and Chlamydia heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001;89244- 250
PubMedArticle
70.
Xu  XHShah  PKFaure  E  et al.  Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;1043103- 3108
PubMedArticle
71.
Kiechl  SLorenz  EReindl  M  et al.  Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347185- 192
PubMedArticle
72.
Boekholdt  SMAgema  WRPeters  RJ  et al.  Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003;1072416- 2421
PubMedArticle
73.
Zee  RYHegener  HHGould  JRidker  PM Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke 2005;36154- 157
PubMedArticle
74.
Laman  JDSchoneveld  AHMoll  FL  et al.  Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques. Am J Cardiol 2002;90119- 123
PubMedArticle
75.
Frantz  SKobzik  LKim  YD  et al.  Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999;104271- 280
PubMedArticle
76.
Dybdahl  BWahba  ALien  E  et al.  Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002;105685- 690
PubMedArticle
77.
Frantz  SKelly  RABourcier  T Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem 2001;2765197- 5203
PubMedArticle
78.
Shishido  TNozaki  NYamaguchi  S  et al.  Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;1082905- 2910
PubMedArticle
79.
Ribas  AButterfield  LHGlaspy  JA  et al.  Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;212415- 2432
PubMedArticle
80.
Tsuji  SMatsumoto  MTakeuchi  O  et al.  Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 2000;686883- 6890
PubMedArticle
81.
Hertz  CJKiertscher  SMGodowski  PJ  et al.  Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 2001;1662444- 2450
PubMedArticle
82.
Whitmore  MMDeVeer  MJEdling  A  et al.  Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004;645850- 5860
PubMedArticle
83.
Aliprantis  AOYang  RBMark  MR  et al.  Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor 2. Science 1999;285736- 739
PubMedArticle
84.
Choi  K-BWong  FHarlan  JM  et al.  1998. Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway. J Biol Chem 1998;27320 185- 20 188
PubMedArticle
85.
Coffey  JCWang  JHSmith  MJBouchier-Hayes  DCotter  TGRedmond  HP Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003;4760- 768
PubMedArticle
86.
Pidgeon  GPHarmey  JKay  E  et al.  The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 1999;811311- 1317
PubMedArticle
87.
Coffey  JCDoyle  MO’Mahony  L  et al.  Probiotics confer protection against perioperative metastatic tumour growth. Ann Surg Oncol 2001;85273- 278
88.
Da Costa  MLRedmond  HPBouchier-Hayes  DJ Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumours and development of organ metastases from circulating tumor cells released following surgery. J Surg Res 2001;101111- 119
PubMedArticle
89.
Hemmi  HKaisho  TTakeuchi  O  et al.  Small antiviral compounds activate immune cells via TLR7 MyD88-dependent signalling pathway. Nat Immunol 2002;3196- 200
PubMedArticle
90.
Okamura  YWatari  MJerud  ES  et al.  The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;27610 229- 10 233
PubMedArticle
91.
Wu  HSZhang  JXWang  LTian  YWang  HRotstein  O Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice. Hepatobiliary Pancreat Dis Int 2004;3250- 253
PubMed
92.
Tsoulfas  GTakahashi  YGanster  RW  et al.  Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transplantation 2002;747- 13
PubMedArticle
93.
Palmer  SMBurch  LHDavis  RD  et al.  The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003;168628- 632
PubMedArticle
94.
Methe  HZimmer  EGrimm  CNabauer  MKoglin  J Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 2004;781324- 1331
PubMedArticle
95.
Aliprantis  AOYang  RBWeiss  DS  et al.  The apoptotic signaling pathway activated by Toll-like receptor 2. EMBO J 2000;193325- 3336
PubMedArticle
96.
Into  TKiura  KYasuda  M  et al.  Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-kappa B activation. Cell Microbiol 2004;6187- 199
PubMedArticle
97.
Han  KJSu  XXu  LG  et al.  Mechanisms of TRIF-induced interferon-stimulated response element and NF-kappa B activation and apoptosis. J Biol Chem 2004;27915 652- 15 661
PubMedArticle
98.
Bannerman  DDTupper  JCKelly  JD  et al.  The Fas-associated death-domain protein suppresses activation of NF-kB by LPS and IL-1B. J Clin Invest 2002;109419- 425
PubMedArticle
Review
June 01, 2006

The Emerging Role of Toll-Like Receptor Pathways in Surgical Diseases

Author Affiliations

Author Affiliations: Department of Surgery, Cork University Hospital, National University of Ireland, Cork (Drs Romics, Coffey, Wang, and Redmond); and Department of Medicine, University of Massachusetts Medical School, Worcester (Dr Szabo).

Arch Surg. 2006;141(6):595-601. doi:10.1001/archsurg.141.6.595
Abstract

Objective  To outline the emerging significance of Toll-like receptor (TLR) signaling pathways in surgical diseases.

Data Sources  A systematic review of the literature was undertaken by searching the MEDLINE database for the period 1966 to 2005 without language restriction.

Study Selection  Original or review articles that described experimental data on the activation of TLR signaling pathways in surgically relevant diseases were selected for inclusion in this review.

Data Extraction  Data were obtained from peer-reviewed articles and references.

Data Synthesis  The role of TLRs in the recognition of pathogens renders them a key figure in the activation of both innate and adaptive immune responses during sepsis. However, emerging evidence points to fundamentally important roles in ulcerative colitis, Crohn disease, and Helicobacter pylori infection in the gastrointestinal tract and in the development of atherosclerotic plaques in the cardiovascular system. Furthermore, recent studies suggest that the regulation of the TLR pathway fulfills a central role in anticancer immunotherapy and in organ rejection after transplantation.

Conclusion  Given the clinical significance of TLR pathways, the targeting of individual molecular components is likely to offer a broad range of future therapeutic modalities.

Toll-like receptors (TLRs) belong to the pattern recognition receptor superfamily that recognizes distinct pathogen-associated molecular patterns. They have a broad range of functions, from being responsible for dorsoventral polarity in the Drosophila embryo1 to protecting the latter from fungal infections.1 Since 1997, 11 members of the mammalian homologue of the Drosophila Toll receptor family have been described.2

Structurally, TLRs consist of a leucine-rich repeat in the extracellular domain and a Toll–interleukin 1 (IL-1) receptor homologous region3 (TIR domain) in their intracellular portion. TLR4 (the so-called endotoxin receptor) recognizes lipopolysaccharide (LPS) present in the cell wall of gram-negative bacteria and also endogenous ligands such as heat shock proteins (HSPs) 60 and 70. TLR2 is responsible for the recognition of peptidoglycans (PGN), lipoteichoic acid (LTA), and bacterial lipoprotein (BLP), as well as zymosan from fungi. TLR3 recognizes double-stranded RNA (dsRNA) from viruses. TLR5 is responsible for bacterial flagellin recognition. TLR9 is important in the recognition of unmethylated CpG DNA derived from bacteria. TLR1, TLR6, and TLR10 can coassociate with TLR2 and subsequently enhance ligand specificity.

Toll-like receptors represent an important link between the “innate” and “adaptive” immune systems. Activation of TLRs triggers nonspecific immune responses in monocytes and macrophages. In addition, TLRs are also found on immature dendritic cells (DCs) and are capable of triggering their maturation. In this manner, DCs matured through TLR activation stimulate specific or adaptive immune responses.

In this article, we review recent data that link various surgical diseases to TLR pathways. We searched the MEDLINE database for the period 1966 to 2005 without language restriction. Original or review articles that described experimental data published in original papers or summarized in review papers on the activation of TLR signaling pathways in surgically relevant diseases were selected for inclusion in this review.

THE SIGNALING PATHWAYS OF TLRs

To better understand the functions of the TLRs, their associated signaling pathways should first be described (Figure 1). TLR4 is the most widely studied TLR. After LPS ligation, TLR4 forms stable clusters (receptosomes) that recruit the adaptor molecule, MD-24 (Figure 1). MD-2–deficient mice are resistant to LPS-induced shock, as are TLR4-mutant and TLR4-deficient mice.5 During gram-negative septic shock, circulating LPS is bound by LPS-binding protein (LBP) in the serum. This complex is subsequently recognized by CD14, which facilitates LPS-induced signaling.6 MD-2 either resides in a complex with TLR4 or is secreted in the serum when in excess.7 Having ligated with TLR4 at the cell surface, LPS is internalized rapidly via an unknown mechanism.

TLR activation induces either a core TLR response or a specific cellular response via the induction of different signaling pathways. As part of the core signaling pathway, myeloid differentiation factor 88 (MyD88) plays a central role (Figure 1). MyD88 interacts with TLRs via their TIR domain. MyD88-deficient mice are unresponsive to LPS,8 and MyD88-deficient macrophages do not respond to PGN and lipoproteins (TLR2 ligand) or CpG DNA (TLR9 ligand). On the other hand, MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection.9 MyD88 deficiency modulates the kinetics of the LPS-induced inflammatory response. The activation of nuclear regulatory factor κB (NF-κB) and c-Jun N-terminal kinases is delayed.10 Given the central role of this molecule in LPS-mediated signal transduction, it represents a potential focal point for future therapies.

Activated MyD88 recruits a death domain–containing serine–threonine kinase, the IL-1 receptor–associated kinase (IRAK) (Figure 1). The IRAK family consists of IRAK-1, -2, -4, and -M isoforms. Notably, IRAK-4–deficient mice are unresponsive to LPS-induced proinflammatory stimulation,11 whereas IRAK-1–deficient mice exhibit a partial attenuation in LPS-induced inflammatory responses. Phosphorylated IRAK associates with tumor necrosis factor (TNF) receptor–associated factor 6 (TRAF6), which leads to the activation of NF-κB and mitogen-activated protein kinase (MAPK) (Figure 1).

A central role has been attributed to TIR domain–containing adaptor proteins (TIRAPs): TIRAP/MyD88- adaptor–like (Mal)12,13 and Toll/IL-1 receptor domain-containing adaptor-inducing interferon β (TRIF) (Figure 1). This suggestion is based on the finding that a dominant negative form of TIRAP/Mal prevents TLR4- but not TLR9-mediated NF-κB activation. Yamamoto et al14 showed that mice deficient in both MyD88 and TRIF exhibit a complete loss of TLR4-mediated NF-κB activation. These data indicate that LPS-triggered NF-κB activation involves either MyD88 or TRIF. These molecules may represent future therapeutic targets in the regulation of TLR-mediated signaling.

TLRs IN SEPSIS AND THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME

Figure 2 summarizes surgical diseases that are currently associated with TLR pathways. Much of the evidence that supports a role for TLR-mediated signaling in sepsis stems from murine studies. TLR4 activation is now known to occur during the systemic inflammatory response syndrome (SIRS). The development of SIRS, after the administration of soluble heparan sulfate or elastase, is TLR4 dependent. In keeping with this observation, Johnson et al15 demonstrated that exogenous macromolecules acting on TLRs can initiate a process that culminates in SIRS.

In humans, up-regulation of TLR4 and TLR2 levels occurs in monocytes isolated from patients with sepsis.16,17 Takeuchi et al9 showed that in murine models of acute polymicrobial sepsis, TLR2, TLR4 messenger (mRNA), and TLR4 protein levels are up-regulated early during polymicrobial sepsis, which correlates with increased mortality. Transgenic mice that overexpress TLR4 are more sensitive to LPS.18 Absence of the TLR4 gene protects against LPS-induced lethality but makes the host more susceptible to gram-negative bacterial infection.19 TLR2 and MyD88 knockout mice show increased susceptibility to S aureus infection compared with wild-type mice.20 In addition, MyD88-deficient mice are more resistant to polymicrobial sepsis.21 This finding points to a common TLR4/TLR2 signaling pathway that follows the activation of both receptors by gram-positive and gram-negative bacteria. Interestingly, TLR4, TLR2, and combined TLR4/TLR2 deficiency do not improve survival in experimental polymicrobial sepsis.22

Several studies2329 point to the importance of genetic alterations in influencing outcome in sepsis. Polymorphisms in the TLR4 gene have been implicated in the development of septic shock. Arbour et al24 showed that common, cosegregating missense mutations (Asp299Gly and Thr399Ile) in the TLR4 gene lead to a blunted inflammatory response after LPS inhalation in humans. Gram-negative infection occurs in a significantly higher percentage of the patients with allelic mutations.25 The Asp299Gly mutation was found to be associated with increased mortality in SIRS.26 In contrast, monocytes separated from heterozygous TLR4 mutation carriers did not demonstrate an altered response to LPS.27,28 However, a coding mutation in the MD-2 gene (TLR4 coreceptor) results in reduced LPS-induced signaling.29

Polymorphisms in the TLR2 gene have been shown to correlate with both the incidence and outcome of septic shock. In vitro, functional studies30 confirmed that cells that express mutant TLR2 are significantly less responsive to TLR2 ligands than wild-type controls. In accordance with this, Meng et al31 demonstrated that an anti-TLR2 antibody prevents a lethal shocklike syndrome in mice.

The clinical significance of genetic alterations in the downstream pathways has been illustrated by Picard et al,32 who recently described the cases of 3 unrelated children with recurrent severe pyogenic bacterial infections. They identified a defect in human TLR-IRAK signaling in these children that resulted in an increased susceptibility to pyogenic bacteria. However, this defect was associated with a relative protection against most other ubiquitous pathogens (Figure 2).

The ability to predict a patient's individual susceptibility to infection would represent an enormously powerful therapeutic advance. Given our emerging understanding of single-nucleotide polymorphisms and given microarray technology, it is foreseeable that a single test, performed before patients undergo surgery, would readily determine susceptibility to infection and thereby guide prophylactic treatments.

Tolerance to bacterial cell wall components represents an adaptive host response during infection. Tolerance may also lead to severe immunosuppression during sepsis. The role of the TLR pathway in the generation of tolerance is somewhat controversial. We and others have demonstrated that the phenomena of homotolerance and heterotolerance occur for ligands of TLR2, TLR4, TLR5, TLR7, and TLR9.3341 Numerous intracellular mechanisms have been implicated in tolerance. Our laboratory has recently demonstrated a down-regulation of TLR2 surface expression in tolerance induced by exposure to low-dose bacterial lipoprotein.33 Other studies38 demonstrate reduced recruitment of MyD88 to TLR4 in LPS-induced tolerance. Emerging mechanisms include the down-regulation of IRAK-1 and IRAK-M as well as reduced colocalization between IRAK isoforms and MyD88.33,3941

Recently it was observed that TLR4 and MD-2 exist in a soluble form in the circulation.4244 Soluble TLR4 attenuates LPS-induced NF-κB activation in vitro.42 Pugin et al43 demonstrated that soluble MD-2 levels are increased in the plasma, urine, and lung edema fluid from patients with severe sepsis. We have shown that increased hepatic LPS sensitivity is associated with transcriptional up-regulation of MD-2 in a mouse model for fulminant hepatic failure.45 Similarly, excessive TLR4 reactivity, which can occur as a “second hit” after severe injury, might lead to multiple organ failure.46

Finally, the high-mobility group box 1 (HMGB1) protein has been shown to bind TLR2 and TLR4.47 Secreted HMGB1 acts a cytokine, and therapeutic administration of HMGB1 antagonists rescues mice from lethal sepsis. Therefore, the interaction of HMGB1 with TLR2 and TLR4 may provide an explanation for the ability of HMGB1 to generate inflammatory responses and accelerate lethality in sepsis.

TLRs IN THE GASTROINTESTINAL TRACT

In normal conditions, intestinal epithelia strongly express TLR3 and TLR5, whereas TLR4 and TLR2 expression is weak.48,49 Rakoff-Nahoum et al50 demonstrated that the interaction between commensal bacteria and TLRs on surface epithelia is crucial to the maintenance of gut epithelial homeostasis and protection against gut injury.

In ulcerative colitis (UC) and Crohn disease (CD), TLR4 expression in primary epithelial cells is increased.51 In contrast, TLR3 expression is down-regulated in active UC but not in active CD. Interestingly, TLR2 and TLR5 levels remain unchanged during both.51 Recent findings indicate that in murine models of experimental colitis, TLR4/MD-2 and CD14 are expressed mainly in distally located colonic epithelial cells, whereas TLR2 is expressed primarily in the proximal colon. This is referred to as TLR compartmentalization in colitis52 (Figure 2).

Nucleotide-binding and oligomerization domain 2 (Nod2), a receptor that is structurally similar to TLRs, is also involved in intracellular LPS recognition. Mutations in the Nod2, TLR4 (Asp299Gly), and TLR9 genes are associated with increased susceptibility to CD.53,54 The Asp299Gly and Thr399Ile TLR4 mutations are associated with a higher incidence of UC.5557

Lodes et al58 showed that the TLR5 agonist, flagellin, is a dominant antigen in CD. Although TLR5 is localized mainly on the basolateral surface of colonic cell lines,49 it occurs mainly at the apical pole of ileal enterocytes.59 TLR5 expression on intestinal endothelial cells (in colonic microvessels) raises the exciting prospect of an overlap between localized innate immune responses and systemic vascular responses.60

Several studies point to a role for TLRs in the recognition of Helicobacter pylori, a crucial pathogenic factor in chronic gastritis, peptic ulcer disease, and gastric neoplasia. TLR4 mRNA levels are up-regulated by H pylori in gastric epithelial cell lines.61 However, H pylori–activated cytokine production occurs independently of TLR4 activation.62 In addition, H pylori–associated flagellin evades TLR5, a property that may contribute to its persistence in the host63 (Figure 2).

TLRs IN VASCULAR AND CARDIAC SURGERY

Chlamydia pneumoniae infection is associated with the development of atherosclerotic plaques.64 Elevated C pneumoniae–derived HSP-60 levels are found in patients with peripheral vascular diseases and in experimental models of atherosclerosis. Elevated serum HSP-60 levels are found in patients with atherosclerosis and even in those with borderline hypertension. Numerous studies65,66 have identified the presence of C pneumoniae in the walls of abdominal aortic aneurysms. These findings point to an association between HSP-60 and early cardiovascular disease.67,68

TLR4 recognizes both the whole bacterium and C pneumonia–derived HSP-60. Chlamydia pneumoniae induces proliferation of human vascular smooth muscle cells. This effect occurs via TLR4-mediated activation of p44/p42 MAPK.69 Furthermore, TLR4 levels are up-regulated in atherosclerotic plaques compared with the normal vessel wall.70 TLR4 polymorphisms have also been associated with the development of atherosclerotic lesions. Evidence is emerging that TLR4 polymorphisms are associated with a protective antiatherosclerotic effect in the clinical setting. Kiechl et al71 demonstrated that the Asp299Gly TLR4 allele is associated with a lower risk of carotid atherosclerosis and a smaller intima media thickness in the common carotid artery, either in the homozygous or heterozygous form. Furthermore, TLR4 polymorphisms are associated with a reduced risk of acute coronary events.72 However, TLR4 polymorphisms do not appear to correlate with a reduced risk of stroke.73 TLR2 has recently been implicated in carotid artery plaques and in particular with the vulnerable plaque phenotype.74 Hence, these findings indicate that the adaptive and/or innate immune response is implicated in atherogenesis and may therefore be modulated with a view to altering the disease (Figure 2).

Frantz et al75 showed increased TLR4 expression on the border of necrotic and viable myocardium. Increased TLR2 and TLR4 levels have been demonstrated in circulating monocytes 2 days after coronary artery bypass grafting.76 In contrast, a protective role has been shown for TLR2. TLR2 has been proved to attenuate the effects of oxidative stress–related NF-κB activation in the myocardium.77 In addition, TLR2 plays an important role in ventricular remodeling after myocardial infarction.78

TLRs IN SURGICAL ONCOLOGY

At present, many forms of immunotherapy exploit a tumor antigen–specific immune response that is initiated by antigen-presenting DCs. Numerous phase 1 and 2 trials are currently under way using autologous DC vaccines against non–small cell lung cancer, melanoma, hepatocellular carcinoma, and gastric, colon, breast, pancreas, prostate, ovarian, and cervical cancer.79 Toll-like receptors play a critical role in DC maturation. In many DC-based vaccines, maturation most likely results from the activation of TLRs by bacillus Calmette-Guérin (BCG) cell wall skeleton, dsRNA, LPS, PGN, lipoprotein, and CpG DNA.80,81 One of the best known adjuvants, BCG cell wall skeleton, is known to induce both TLR2 and TLR4.80 Imiquimod, a synthetic antitumor agent, is a TLR7 ligand. Synergistic activation of TLR3 and TLR9 resulted in an enhanced antimetastatic effect, as demonstrated by Whitmore et al82 (Figure 2). Toll-like receptor signaling also critically overlaps with apoptotic cascades. The regulation of apoptosis by TLR ligands represents an attractive anticancer treatment modality. TLR2 activation induces apoptosis in macrophages and endothelial cells by recruiting MyD88, IRAK-1, and the Fas-associated death domain (FADD)–caspase 8 (and hence the extrinsic) proapoptotic pathway.83,84

There is increasing evidence, albeit indirect, that implicates LPS (and therefore TLR) signaling in the accelerated growth of minimal residual neoplastic disease after excisional surgery for cancer cure. It is well accepted that after surgical stress, local and systemic neoplastic disease is potentiated and undergoes acceleration in growth.85 Although multiple mechanisms have been implicated in this phenomenon, enhanced bacterial translocation and systemic endotoxemia are directly correlated.86 We have demonstrated that antiendotoxin agents, such as taurolidine and probiotics, exert a protective effect against accelerated metastatic tumor growth after surgery.87,88 Overall, these findings strongly implicate LPS signaling, and by definition TLR signaling, in the acceleration of metastatic tumor growth that follows excisional surgery for apparent cancer cure.

TLRs IN TRANSPLANTATION

Dendritic cells play a role in graft rejection after transplantation. The role of TLR signaling has been investigated in this regard. Hemmi et al89 showed that minor antigen-mismatched acute rejection does not occur in MyD88-deficient mice. This experimental observation correlates with the presence of decreased numbers of mature DCs in draining lymph nodes. An investigation of the ischemia-reperfusion injury after liver transplantation revealed that TLR2, CD14, and LBP levels were increased within 6 to 12 hours after liver transplantation90 and also that TLR4 deficiency attenuated hepatic ischemia-reperfusion injury.91 These findings indicate that multiple components of the LPS signaling pathway are activated during ischemia-reperfusion injury after liver transplantation.92 In keeping with this, TLR4 polymorphisms are associated with decreased acute rejection after lung transplantation.93 Regarding heart transplantation, allograft endothelial dysfunction is associated with elevated TLR4 levels on peripheral blood monocytes.94 Endothelial dysfunction is an early indicator of chronic rejection after cardiac transplantation. These data demonstrate that TLR pathways contribute to organ rejection and ischemia-reperfusion injury after liver transplantation (Figure 2).

COMMENT

Toll-like receptors recognize specific patterns present in molecules within microbes and then regulate the activation of both innate and adaptive immunity. Currently it is unclear whether the net effect of TLR activation is beneficial or detrimental to the host. Although TLR4 deficiency increases susceptibility to gram-negative bacterial sepsis, it protects against endotoxin-induced sepsis.18,19,22 Similarly, TLR2-deficient mice are more susceptible to S aureus infection then are their wild-type counterparts.20 In humans, TLR4 polymorphisms are associated with an increased incidence of gram-negative sepsis2426 but inflammatory hyporesponsiveness to selective ligands and inhaled LPS.24 Similarly, patients with certain types of TLR2 polymorphisms are at increased risk of life-threatening staphylococcal infections.95 These data indicate that defective TLR signaling is detrimental to the host in bacterial infection. However, when bacterial cell wall components are used as ligands, defective TLR signaling appears protective. The whole bacterium theoretically might activate other, as yet unknown, pattern recognition receptors besides TLRs. These receptors may interfere with the TLR signaling process or trigger the production of different effector molecules, resulting in an altered cytokine environment.

The complexity of signaling pathways triggered by TLRs has been extensively characterized. Some of these studies have focused on the relationship between inflammatory and apoptotic pathways. Apoptotic pathways can be activated by death receptors of the TNF family such as Fas, TNF receptor 1, or the TNF-related apoptosis-inducing ligand (TRAIL) receptors. The apoptotic cascade is activated after the recruitment of the adaptor protein FADD. Interestingly, TLR2, TLR3, and TLR4 are also able to recruit FADD. TLR2 in association with activated TLR6 will recruit FADD, whereas TLR3 recruits FADD via TRIF.9597 Bannerman et al98 demonstrated that TLRs simultaneously trigger proapoptotic (FADD) and antiapoptotic (NF-κB) signaling pathways. It is reasonable to speculate that after TLR activation, certain intracellular regulatory mechanisms may direct the cell either to undergo cell death or to persist and subsequently generate an inflammatory response. Understanding cross-talk between inflammatory and apoptotic pathways will greatly affect the treatment of septic and neoplastic diseases.

The recent increase in TLR research has identified novel associations with numerous disease processes. Although these associations will undoubtedly enhance our understanding of these diseases, they should also generate novel therapeutic targets. More important, the diverse role of TLR signaling pathways in numerous surgical diseases strongly points to an overlap in terms of pathogenesis. The suggestion therefore arises that conditions formerly associated with different molecular processes may involve common signaling pathways. This is an enticing prospect, since the therapeutic subversion of these pathways may greatly simplify the treatment of surgical disease. Such is the current level of understanding of the TLR signaling processes, and the components thereof, that it may soon be possible to therapeutically dissect these pathways by selectively targeting adaptor molecules (Mal/TIRAP, TRIF, TRAM, and MyD88) or coreceptors (MD-2 and CD14). We suggest that the therapeutic manipulation of TLR signaling will ultimately find its place at the bedside and represent a powerful adjuvant in the management of surgical disease.

Back to top
Article Information

Correspondence: Henry Paul Redmond, BSc, MCh, FRCSI, Department of Surgery, Cork University Hospital, Wilton Road, Wilton, Cork, Ireland (redmondhp@shb.ie), or Gyongyi Szabo, MD, PhD, Department of Medicine, University of Massachusetts Medical School, 364 Plantation St, LRB 215, Worcester, MA 01605-2324 (Gyongyi.Szabo@umassmed.edu).

Accepted for Publication: June 1, 2005.

Funding/Support: This work was supported by the Irish Research Council for Science, Engineering and Technology Basic Research Grants Scheme (SC/2003/27), the Health Research Board in Ireland, and the Hungarian State Scholarship “Eotvos” (2001).

References
1.
Lemaitre  BNicolas  EMichaut  L  et al.  The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86973- 983
PubMedArticle
2.
Iwasaki  AMedzhitov  R Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5987- 995
PubMedArticle
3.
Medzhitov  R Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1135- 145
PubMedArticle
4.
Visintin  ALatz  EMonks  BG  et al.  Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem 2003;27848 313- 48 320
PubMedArticle
5.
Nagai  YAkashi  SNagafuku  M  et al.  Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002;3667- 672
PubMed
6.
Jiang  QAkashi  SMiyake  K  et al.  Cutting edge: lipopolysaccharide induces physical proximity between CD14 and Toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-B. J Immunol 2000;1653541- 3544
PubMedArticle
7.
Visintin  AMazzoni  ASpitzer  JA  et al.  Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci U S A 2001;9812156- 12161. Epub 2001 Oct 2
PubMedArticle
8.
Kawai  TAdachi  OOgawa  T  et al.  Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999;11115- 122
PubMedArticle
9.
Takeuchi  OHoshino  KAkira  S Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000;1655392- 5396
PubMedArticle
10.
Takeuchi  OKaufmann  AGrote  K  et al.  Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway. J Immunol 2000;164554- 557
PubMedArticle
11.
Suzuki  NSuzuki  SDuncan  GS  et al.  Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4. Nature 2002;416750- 756
PubMedArticle
12.
Horng  TBarton  GMMedzhitov  R TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2001;2835- 841
PubMedArticle
13.
Fitzgerald  KAPalsson-McDermott  EMBowie  AG  et al.  Mal (MyD88-adaptor-like) is required for Toll-like receptor-4 signal transduction. Nature 2001;41378- 83
PubMedArticle
14.
Yamamoto  MSato  SHemmi  H  et al.  Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 2003;301640- 643
PubMedArticle
15.
Johnson  GBBrunn  GJPlatt  JL Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol 2004;17220- 24
PubMedArticle
16.
Armstrong  LMedford  ARHunter  KJUppington  KMMillar  AB Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol 2004;136312- 319
PubMedArticle
17.
Harter  LMica  LStocker  RTrentz  OKeel  M Increased expression of toll-like receptor-2 and -4 on leukocytes from patients with sepsis. Shock 2004;22403- 409
PubMedArticle
18.
Bihl  FSalez  LBeaubier  M  et al.  Overexpression of Toll-Like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J Immunol 2003;1706141- 6150
PubMedArticle
19.
Wang  MJeng  KCPing  LI Exogenous cytokine modulation or neutralization of interleukin-10 enhance survival in lipopolysaccharide-hyporesponsive C3H/HeJ mice with Klebsiella infection. Immunology 1999;9890- 97
PubMedArticle
20.
Williams  DLHa  TLi  C  et al.  Modulation of tissue Toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit Care Med 2003;311808- 1818
PubMedArticle
21.
Weighardt  HKaiser-Moore  SVabulas  RM  et al.  Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol 2002;1692823- 2827
PubMedArticle
22.
Feterowski  CEmmanuilidis  KMiethke  T  et al.  Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 2003;109426- 431
PubMedArticle
23.
Holmes  CLRussell  JAWalley  KR Genetic polymorphism in sepsis and septic shock. Chest 2003;1241103- 1115
PubMedArticle
24.
Arbour  NCLorenz  ESchutte  BC  et al.  TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25187- 191
PubMedArticle
25.
Agnese  DMCalvano  JEHahm  SJ  et al.  Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;1861522- 1525
PubMedArticle
26.
Lorenz  EMira  JPFrees  KL  et al.  Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002;1621028- 1032
PubMedArticle
27.
Erridge  CStewart  JPoxton  IR Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003;1971787- 1791
PubMedArticle
28.
Imahara  SDJelacic  SJunker  CEO'Keefe  GE The TLR4 +896 polymorphism is not associated with lipopolysaccharide hypo-responsiveness in leukocytes. Genes Immun 2005;637- 43
PubMedArticle
29.
Hamann  LKumpf  OMuller  M  et al.  A coding mutation within the first exon of the human MD-2 gene results in decreased lipopolysaccharide-induced signaling. Genes Immun 2004;5283- 288
PubMedArticle
30.
Lorenz  EMira  JPCornish  KL  et al.  A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000;686398- 6401
PubMedArticle
31.
Meng  GRutz  MSchiemann  M  et al.  Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 2004;1131473- 1481
PubMedArticle
32.
Picard  CPuel  ABonnet  M  et al.  Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003;2992076- 2079
PubMedArticle
33.
Wang  JHDoyle  MManning  BJ  et al.  Induction of bacterial lipoprotein tolerance is associated with suppression of Toll-like receptor 2 expression. J Biol Chem 2002;27736 068- 36 075
PubMedArticle
34.
Dobrovolskaia  MAMedvedev  AEThomas  KE  et al.  Induction of in vitro reprogramming by Toll-Like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR “homotolerance” versus “heterotolerance” on NF-kB signaling pathway components. J Immunol 2003;170508- 519
PubMedArticle
35.
Sato  STakeuchi  OFujita  T  et al.  A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. Int Immunol 2002;14783- 791
PubMedArticle
36.
Medvedev  AEHenneke  PSchromm  A  et al.  Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J Immunol 2001;1672257- 2267
PubMedArticle
37.
Mizel  SBSnipes  JA Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from Toll-like receptor 5. J Biol Chem 2002;27722 414- 22 420
PubMedArticle
38.
Medvedev  AELentschat  AWahl  LM  et al.  Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 2002;1695209- 5216
PubMedArticle
39.
Kobayashi  KHernandez  LDGalaìn  JE  et al.  IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002;110191- 202
PubMedArticle
40.
Wang  JHDoyle  MManning  BJ  et al.  Cutting edge: bacterial lipoprotein induces endotoxin-independent tolerance to septic shock. J Immunol 2003;17014- 18
PubMedArticle
41.
O'Brien  GCWang  JHRedmond  HP Bacterial lipoprotein induces resistance to gram-negative sepsis in TLR4-deficient mice via enhanced bacterial clearance. J Immunol 2005;1741020- 1026
PubMedArticle
42.
Iwami  KIMatsuguchi  TMasuda  A  et al.  Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2000;1656682- 6686
PubMedArticle
43.
Pugin  JStern-Voeffray  SDaubeuf  BMatthay  MAElson  GDunn-Siegrist  I Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood 2004;1044071- 4079
PubMedArticle
44.
Kennedy  MNMullen  GELeifer  CA  et al.  A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem 2004;27934 698- 34 704
PubMedArticle
45.
Romics  L  JrDolganiuc  AKodys  K  et al.  Selective priming to Toll-like receptor 4 (TLR4), not TLR2, ligands by P. acnes involves up-regulation of MD-2. Hepatology 2004;40555- 564
PubMedArticle
46.
Murphy  TJPaterson  HMKriyonovich  S  et al.  Linking the “two-hit” response following injury to enhanced TLR4 reactivity. J Leukoc Biol 2005;7716- 23
PubMed
47.
Park  JSSvetkauskaite  DHe  Q  et al.  Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;2797370- 7377
PubMedArticle
48.
Abreu  MTVora  PFaure  E  et al.  Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;1671609- 1616
PubMedArticle
49.
Gewirtz  ATNavas  TALyons  S  et al.  Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001;1671882- 1885
PubMedArticle
50.
Rakoff-Nahoum  SPaglino  JEslami-Varzaneh  FEdberg  SMedzhitov  R Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118229- 241
PubMedArticle
51.
Cario  EPodolsky  DK Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;687010- 7017
PubMedArticle
52.
Ortega-Cava  CFIshihara  SRumi  MAK  et al.  Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol 2003;1703977- 3985
PubMedArticle
53.
Hugot  JPChamaillard  MZouali  H  et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411599- 603
PubMedArticle
54.
Ogura  YBonen  DKInohara  N  et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411603- 606
PubMedArticle
55.
Rachmilewitz  DKatakura  KKarmeli  F  et al.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126520- 528
PubMedArticle
56.
Torok  HPGlas  JTonenchi  LMussack  TFolwaczny  C Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004;11285- 91
PubMedArticle
57.
Franchimont  DVermeire  SEl Housni  H  et al.  Deficient host-bacteria interactions in inflammatory bowel disease? the toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004;53987- 992
PubMedArticle
58.
Lodes  MJCong  YElson  CO  et al.  Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;1131296- 1306
PubMedArticle
59.
Bambou  JCGiraud  AMenard  S  et al.  In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain. J Biol Chem 2004;27942 984- 42 992
PubMedArticle
60.
Maaser  CHeidemann  Jvon Eiff  C  et al.  Human intestinal microvascular endothelial cells express Toll-like receptor 5: a binding partner for bacterial flagellin. J Immunol 2004;1725056- 5062
PubMedArticle
61.
Su  BCeponis  PJMLebel  S  et al.  Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect Immun 2003;713496- 3502
PubMedArticle
62.
Bäckhed  FRokbi  BTorstensson  E  et al.  Gastric mucosal recognition of Helicobacter pylori is independent of Toll-like receptor 4. J Infect Dis 2003;187829- 836
PubMedArticle
63.
Gewirtz  ATYu  YKrishna  USIsrael  DALyons  SLPeek  RM  Jr Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004;1891914- 1920
PubMedArticle
64.
Wald  NJLaw  MRMorris  JK  et al.  Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 2000;321204- 207
PubMedArticle
65.
Petersen  EBoman  JPersson  K  et al.  Chlamydia pneumoniae in human abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1998;15138- 142
PubMedArticle
66.
Juvonen  JJuvonen  TLaurila  K  et al.  Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997;25499- 505
PubMedArticle
67.
Xu  QSchett  GPerschinka  H  et al.  Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 2000;10214- 20
PubMedArticle
68.
Pockley  AGWu  RLemne  CKiessling  Rde Faire  UFrostegard  J Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension 2000;36303- 307
PubMedArticle
69.
Sasu  SLaVerda  DQureshi  N  et al.  Chlamydia pneumoniae and Chlamydia heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001;89244- 250
PubMedArticle
70.
Xu  XHShah  PKFaure  E  et al.  Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;1043103- 3108
PubMedArticle
71.
Kiechl  SLorenz  EReindl  M  et al.  Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347185- 192
PubMedArticle
72.
Boekholdt  SMAgema  WRPeters  RJ  et al.  Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003;1072416- 2421
PubMedArticle
73.
Zee  RYHegener  HHGould  JRidker  PM Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke 2005;36154- 157
PubMedArticle
74.
Laman  JDSchoneveld  AHMoll  FL  et al.  Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques. Am J Cardiol 2002;90119- 123
PubMedArticle
75.
Frantz  SKobzik  LKim  YD  et al.  Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999;104271- 280
PubMedArticle
76.
Dybdahl  BWahba  ALien  E  et al.  Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002;105685- 690
PubMedArticle
77.
Frantz  SKelly  RABourcier  T Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem 2001;2765197- 5203
PubMedArticle
78.
Shishido  TNozaki  NYamaguchi  S  et al.  Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;1082905- 2910
PubMedArticle
79.
Ribas  AButterfield  LHGlaspy  JA  et al.  Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;212415- 2432
PubMedArticle
80.
Tsuji  SMatsumoto  MTakeuchi  O  et al.  Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 2000;686883- 6890
PubMedArticle
81.
Hertz  CJKiertscher  SMGodowski  PJ  et al.  Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 2001;1662444- 2450
PubMedArticle
82.
Whitmore  MMDeVeer  MJEdling  A  et al.  Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004;645850- 5860
PubMedArticle
83.
Aliprantis  AOYang  RBMark  MR  et al.  Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor 2. Science 1999;285736- 739
PubMedArticle
84.
Choi  K-BWong  FHarlan  JM  et al.  1998. Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway. J Biol Chem 1998;27320 185- 20 188
PubMedArticle
85.
Coffey  JCWang  JHSmith  MJBouchier-Hayes  DCotter  TGRedmond  HP Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003;4760- 768
PubMedArticle
86.
Pidgeon  GPHarmey  JKay  E  et al.  The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 1999;811311- 1317
PubMedArticle
87.
Coffey  JCDoyle  MO’Mahony  L  et al.  Probiotics confer protection against perioperative metastatic tumour growth. Ann Surg Oncol 2001;85273- 278
88.
Da Costa  MLRedmond  HPBouchier-Hayes  DJ Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumours and development of organ metastases from circulating tumor cells released following surgery. J Surg Res 2001;101111- 119
PubMedArticle
89.
Hemmi  HKaisho  TTakeuchi  O  et al.  Small antiviral compounds activate immune cells via TLR7 MyD88-dependent signalling pathway. Nat Immunol 2002;3196- 200
PubMedArticle
90.
Okamura  YWatari  MJerud  ES  et al.  The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;27610 229- 10 233
PubMedArticle
91.
Wu  HSZhang  JXWang  LTian  YWang  HRotstein  O Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice. Hepatobiliary Pancreat Dis Int 2004;3250- 253
PubMed
92.
Tsoulfas  GTakahashi  YGanster  RW  et al.  Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transplantation 2002;747- 13
PubMedArticle
93.
Palmer  SMBurch  LHDavis  RD  et al.  The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003;168628- 632
PubMedArticle
94.
Methe  HZimmer  EGrimm  CNabauer  MKoglin  J Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 2004;781324- 1331
PubMedArticle
95.
Aliprantis  AOYang  RBWeiss  DS  et al.  The apoptotic signaling pathway activated by Toll-like receptor 2. EMBO J 2000;193325- 3336
PubMedArticle
96.
Into  TKiura  KYasuda  M  et al.  Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-kappa B activation. Cell Microbiol 2004;6187- 199
PubMedArticle
97.
Han  KJSu  XXu  LG  et al.  Mechanisms of TRIF-induced interferon-stimulated response element and NF-kappa B activation and apoptosis. J Biol Chem 2004;27915 652- 15 661
PubMedArticle
98.
Bannerman  DDTupper  JCKelly  JD  et al.  The Fas-associated death-domain protein suppresses activation of NF-kB by LPS and IL-1B. J Clin Invest 2002;109419- 425
PubMedArticle
×